News | Structural Heart | March 04, 2023

New Data Show Superiority of Abbott's TriClip Device Compared to Medical Therapy for Tricuspid Regurgitation

Late-breaking data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine demonstrate TriClip was superior to medical therapy with significant improvements in quality of life and tricuspid regurgitation (TR)

Late-breaking data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine demonstrate TriClip was superior to medical therapy with significant improvements in quality of life and tricuspid regurgitation (TR)

March 4, 2023 — Abbott announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a first-of-its-kind minimally invasive device designed specifically for tricuspid heart valve repair. The TRILUMINATE Pivotal study evaluates the superiority of TriClip compared to medical therapy in treating patients with severe, symptomatic tricuspid regurgitation (TR) who are at intermediate or greater risk for open-heart surgery.

The results were presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) held in New Orleans (March 4-6, 2023). These data were simultaneously published in The New England Journal of Medicine

Key Findings From the TRILUMINATE Pivotal Study
The trial met its composite primary endpoint demonstrating superiority of the TriClip system compared to the control group (win ratio 1.48, p=0.02), primarily driven by improvement in quality of life. Mortality or tricuspid valve surgery and heart failure hospitalizations did not appear different between the groups at one year. Other positive findings include: 

  • Significant reduction in TR grade. Significant reduction in TR to moderate or less (grade < 2) was achieved in 87% of patients with the device at 30 days vs. 4.8% in the control group, with TR reduction sustained and durable at one year.
  • Significant improvement in quality of life. 50% of patients who received the device achieved at least a 15-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of social abilities, symptoms and quality of life) at one year vs. 26% in the control group.
  • A strong safety profile. At 30 days, only 1.7% of patients who received the device experienced major adverse events, with no urgent surgery or endocarditis. There were no occurrences of device embolization or device thrombus.

"These TRILUMINATE Pivotal trial results are promising because there have historically been very few treatment options for tricuspid regurgitation, and patients with this condition are often not eligible for open-heart surgery due to multiple co-morbidities or other factors," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital. "The trial data and real-world use in Europe from the bRIGHT post-approval study show TriClip's ability to safely and effectively repair the tricuspid valve in patients and improve their quality of life."

"These TRILUMINATE Pivotal data show TriClip is the first minimally invasive device therapy for the treatment of tricuspid regurgitation to provide durable improvements in TR severity and quality of life that go beyond taking medication to manage symptoms," said Michael Dale, senior vice president of Abbott's structural heart business. "When left unaddressed, TR can be debilitating and life-threatening. By repairing the damage caused by structural heart disease, TriClip G4 and our latest technological innovations are helping people reclaim their lives so they can get back to doing what they love."

Abbott will also be presenting at ACC late-breaking five-year results from its landmark COAPT trial of the MitraClip TEER device for functional mitral regurgitation in heart failure.  

For more information: www.abbott.com

Find more ACC23 conference coverage here

 

Related Transcatheter Tricuspid Valve Repair Content:

Transcatheter Tricuspid Valve Repair Clip Device Cleared in Europe

Edwards Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe

First Human Use of Transcatheter Duo Tricuspid Valve Announced in Ireland

VIDEO: Tricuspid Valve Imaging and Interventions Developing Hand-in-hand — Interview with Rebecca Hahn, M.D.

Advances in Transcatheter Tricuspid Valve Technologies

VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

8 Cardiovascular Technologies to Watch in 2020

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study


Related Content

News | Structural Heart

March 14, 2023 — The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the ...

Home March 14, 2023
Home
News | Structural Heart

March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure ...

Home March 05, 2023
Home
News | Structural Heart

February 6, 2023 — University of Virginia researchers and their collaborators have identified genes that play key roles ...

Home February 06, 2023
Home
News | Structural Heart

January 19, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest ...

Home January 19, 2023
Home
News | Structural Heart

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
News | Structural Heart

December 2, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home December 02, 2022
Home
News | Structural Heart

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home November 30, 2022
Home
News | Structural Heart

November 30, 2022 — Medtronic’s newest generation self-expanding, transcatheter aortic valve replacement (TAVR) system ...

Home November 30, 2022
Home
News | Structural Heart

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ...

Home September 26, 2022
Home
News | Structural Heart

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter ...

Home September 20, 2022
Home
Subscribe Now